<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title40.html">
                                    Title 40
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/40CFR158.html">Part 158
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 158.34  Flagging of studies for potential adverse effects.
                            </h3>
                            <p class="depth1"><em>(a)</em> Any applicant who submits a study of a type listed in paragraph (b) of this section must submit with the study a statement in accordance with paragraph (c) of this section.</p><p class="depth1"><em>(b)</em> The following table indicates the study types and the criteria to be applied to each. Column 1 lists the study types by name. Column 2 lists the associated Pesticide Assessment Guideline number. Column 3 lists the criteria applicable to each type of study. Column 4 lists the reporting code to be included in the statement specified in paragraph (c) of this section when any criterion is met or exceeded.</p><p class="depth2">Table--Flagging Criteria----------------------------------------------------------------------------------------------------------------</p><p class="depth2">Criteria: Treated animals show     Criteria</p><p class="depth2">Study Type(s)                    Guideline No.         any of the following:            No.----------------------------------------------------------------------------------------------------------------Carcinogenicity or combined carcinogenicity/           870.4200   An incidence of neoplasms in                 1</p><p class="depth2">chronic feeding study                                 870.4300    males or females which increases</p><p class="depth2">with dose (positive trend</p><p class="depth2">p<=0.05); or</p><p class="depth2">A statistically significant                  2</p><p class="depth2">(pairwise p<=0.05) increase of</p><p class="depth2">any type of neoplasm in any test</p><p class="depth2">group, males or females at any</p><p class="depth2">dose level, compared to</p><p class="depth2">concurrent control animals of</p><p class="depth2">the same sex; or</p><p class="depth2">An increase in any type of                   3</p><p class="depth2">uncommon or rare neoplasms in</p><p class="depth2">any test group, males or females</p><p class="depth2">animals at any dose level,</p><p class="depth2">compared to concurrent controls</p><p class="depth2">of the same sex; or</p><p class="depth2">A decrease in the time to                    4</p><p class="depth2">development of any type of</p><p class="depth2">neoplasms in any test group,</p><p class="depth2">males or females at any dose</p><p class="depth2">level, compared to concurrent</p><p class="depth2">controls of the same sex.----------------------------------------------------------------------------------------------------------------Prenatal developmental toxicity                        870.3700   When compared to concurrent                  5Reproduction and fertility.....................        870.3800    controls, treated offspring showDevelopmental neurotoxicity....................        870.6300    a dose-related increase in</p><p class="depth2">malformations, pre- or post-</p><p class="depth2">natal deaths, or persistent</p><p class="depth2">functional or behavioral changes</p><p class="depth2">on a litter basis in the absence</p><p class="depth2">of significant maternal toxicity</p><p class="depth2">at the same dose level.----------------------------------------------------------------------------------------------------------------Neurotoxicity                                          870.6100   When compared to concurrent                  6</p><p class="depth2">870.6200    controls, treated animals show a</p><p class="depth2">statistically or biologically</p><p class="depth2">significant increase in</p><p class="depth2">neuropathological lesions or</p><p class="depth2">persistent functional or</p><p class="depth2">behavioral changes.----------------------------------------------------------------------------------------------------------------Chronic feeding                                        870.4100   The no observed adverse effect               7Carcinogenicity................................        870.4200    level (NOAEL) from one of theseReproduction and fertility.....................        870.3800    studies is less than the NOAELPrenatal developmental toxicity................        870.3700    currently used by the Agency asDevelopmental neurotoxicity....................        870.6300    the basis for either the acuteAcute or 90-day neurotoxicity..................        870.6200    or chronic reference dose.----------------------------------------------------------------------------------------------------------------</p><p class="depth1"><em>(c)</em> Identification of studies. For each study of a type identified in paragraph (b) of this section, the applicant shall include the appropriate one of the following two statements, together with the signature of the authorized representative of the company, and the date of signature:</p><p class="depth2"><em>(1)</em> Study does not meet or exceed criteria.</p><p class="depth3">I have applied the criteria of 40 CFR 158.34 for flagging studies for potential adverse effects to the results of the attached study. This study neither meets nor exceeds any of the applicable criteria.</p><p class="depth2"><em>(2)</em> Study meets or exceeds criteria.</p><p class="depth3">I have applied the criteria of 40 CFR 158.34 for flagging studies for potential adverse effects to the results of the attached study. This study meets or exceeds the criteria numbered [insert all applicable reporting codes].</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
